| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Alkermes plc | Diroximel fumarate (BIIB098) - (Head-to-head trial versus Tecfidera) | Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Trial Completed | Oral | Neurology |
| Allakos Inc. | Lirentelimab - (ENIGMA 2) | Eosinophilic Gastritis and/or eosinophilic duodenitis (EoD) | Phase 3 | Trial Discontinued | Intravenous | Gastroenterology |
| Allakos Inc. | Lirentelimab - (EoDyssey) | Eosinophilic Gastritis and/or eosinophilic duodenitis (EoD) | Phase 3 | Data Released | Intravenous | Gastroenterology |
| Allakos Inc. | Lirentelimab - (KRYPTOS) | Eosinophilic esophagitis | Phase 2/3 | Trial Discontinued | Intravenous | Gastroenterology |
| Allakos Inc. | Lirentelimab (AK002) - (MAVERICK) | Chronic Spontaneous Urticaria | Phase 2/3 | Trial Discontinued | Intravenous | Immunology |
| Allakos Inc. | Lirentelimab (subcutaneous) | Eosinophilic gastritis (EG) / eosinophilic duodenitis (EoD) | Phase 2/3 | Trial Discontinued | Subcutaneous | Gastroenterology |
| Allakos Inc. | Lirentelimab - (EoDyssey) | Eosinophilic Gastritis and/or eosinophilic duodenitis (EoD) | Phase 3 | Data Released | Intravenous | Gastroenterology |
| Allarity Therapeutics Inc. | Stenoparib in combination with temozolomide | Small Cell Lung Cancer (SCLC) | Phase 2 | Trial Planned | Oral | Oncology |